Case Study: Accelerated Enrollment

A biotech company approached Elligo for help with a CRC screening study. CRC is the third-most common cancer in both men and women in the U.S.,* the second-deadliest cancer globally, and is projected to cause nearly 53,000 deaths in 2021 in the U.S. alone.*

The objective of the study was to perform analytical verification for a multi-target stool RNA-FIT assay. Recruitment for this study utilized a decentralized model, and it was estimated that participants recruited for this study could be found from all 48 contiguous states. Find out the results in the available case study.